The Supply Problem

Organ transplantation is one of the clearest successes in modern medicine. A failing organ is removed and a working one takes its place, and people who would have died live for decades. The limiting factor is not really surgical skill or immunology any more. It is arithmetic. There are far more people who need organs than there are organs, and a large number of people die waiting. Almost everything interesting happening in this field is an attempt to change that number.

Keeping organs alive outside the body

For decades a donated organ was packed in ice and raced to the recipient. Cold slows decay, but it does nothing to repair damage and it offers no way to check whether the organ actually works. That changed with machine perfusion, which keeps an organ working outside the body. The organ is hooked up to a pump that pushes an oxygen-rich fluid through it, sometimes kept at body temperature, so it carries on functioning.

This does two things at once. It allows clinicians to test an organ before committing a patient to it, and it gives the organ a chance to recover from injury. A randomized trial in liver transplantation showed advantages over cold storage1, and for lungs, which are especially fragile, ex vivo lung perfusion, meaning perfusion carried out outside the body, has let surgeons test, repair, and successfully transplant organs that would once have been rejected as too risky Approved2.

The fastest way to add organs may be to stop discarding the ones we already have.

Organs from another species

If the shortage cannot be solved with human donors, the alternative is to look elsewhere. Pig organs are close to the right size and physiology, and the historical obstacle was immediate, violent rejection. Gene editing changed the calculation by allowing many edits at once, removing pig genes that trigger human rejection and adding human genes that calm it.

The first gene-edited pig kidney was transplanted into a living person in March 2024. Since then the field has moved from individual compassionate-use cases into regulated clinical trials, with the first transplant in a formal multi-patient study performed in November 2025 In trials34. The results so far are genuinely early and mixed. Several grafts have been lost to rejection or complications, and the longest reported survival with a pig kidney is under a year. It would be dishonest to describe this as solved. It is equally dishonest to call it science fiction, because it is now happening in trials with regulatory oversight.

Growing tissue rather than borrowing it

The most ambitious approach is to build organs outright. Three lines of work are underway. Organoids are small clumps of tissue grown from stem cells that reproduce part of an organ's structure, and they are already valuable for studying disease and testing drugs. Decellularized scaffolds take an existing organ, wash away all of its cells, and leave the empty framework behind to be filled with new ones. Bioprinting builds tissue layer by layer.

None of these currently produce a transplantable whole organ, and the reason is almost always the same: blood supply. A working organ needs a dense, branching network of blood vessels reaching every single cell. Building that network, a problem called vascularization, is still the central unsolved obstacle. Early research Partial repairs and engineered patches are far closer than whole organs.

A pipeline rather than a breakthrough

If organ failure becomes a manageable condition rather than a terminal one, it will not be because of a single invention. It will be because better preservation reduced waste, expanded donor pathways added supply, gene-edited animal organs filled part of the gap, and engineered tissue handled repairs. Each of those has real momentum. None of them is sufficient alone.